Glioblastoma multiforme is a type of brain tumour. When it is first diagnosed, patients might be treated with surgery and then a combination of radiotherapy and chemotherapy with temozolomide (TMZ).
Unfortunately, although this often slows or stops the disease from growing for a period of time, in most cases, usually a few months after the end of the original treatment, the tumour starts to grow again. This can be detected by an MRI scan. When this happens patients may experience new symptoms or a repeat of previous symptoms.
There are few treatments available that work well at this stage to slow the growth of the tumour. Therefore, we need to develop new and better treatments to make patients live longer and feel better.
The ARISTOCRAT trial is investigating whether adding a second drug (Sativex, a cannabinoid or cannabis-based medicine) to the drug already used, TMZ, works better than TMZ alone. TMZ is the chemotherapy drug that patients will have had before, both with radiotherapy and then afterwards by itself.
The trial will recruit patients with recurrent glioblastoma to find out whether the addition of Sativex to standard TMZ treatment improves how long patients live, delays the growth of their tumour and/or improves their quality of life.